The Hepatitis B tests market size was valued at $1.26 billion in 2021. Hepatitis B is a viral infection caused by the Hepatitis B virus (HBV). The virus attacks the liver and can cause acute and chronic disease, which might lead to liver failure, liver cancer or liver cirrhosis, kidney disease, and/or inflammation of blood vessels. The virus can be transmitted through blood or other bodily fluids by transfusion, sexual contact, sharing of needles, accidental needle sticks, and mother-to-child transmission. Incidence and prevalence rates of hepatitis B infections vary dramatically across countries and geographical regions.
Hepatitis B tests market overview
For more insights on this report, download a free report sample
What are the market dynamics in the Hepatitis B tests market?
Hepatitis B is a common cause of liver disease across the globe. The World Health Organization (WHO) recommends that all infants receive the hepatitis B vaccination and universal vaccinations have now been implemented in numerous countries worldwide. These vaccination programs have successfully reduced the prevalence of hepatitis B in children. However, some children continue to be infected due to maternal-to-child transmission, especially in high-prevalence countries.
While there is no specific treatment for acute hepatitis B, chronic hepatitis B can be treated with antiretroviral agents. While these drugs rarely cure HBV infection, they have been shown to improve overall survival. As they become more accessible, anti-retroviral agents may positively impact survival and thus hepatitis B prevalence in adult patients.
Which are the key regions in the Hepatitis B tests market?
The key regions in the Hepatitis B tests market are North America, Europe, Asia Pacific, South America, and the Middle East and Africa.
What are the key segments in the Hepatitis B tests market?
The key segments in the Hepatitis B tests market are Hepatitis B Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) Tests, Hepatitis B Nucleic Acid Amplification Tests (NAATs), and Multi-parameter HIV, Hepatitis B, and Hepatitis C NAAT.
Hepatitis B tests market, by segments
For more segment insights, download a free report sample
Which are the key companies in the Hepatitis B tests market?
Some of the key companies in the Hepatitis B tests market are Abbott Laboratories, Bio-Rad Laboratories Inc, Hologic Inc, Ortho Clinical Diagnostics Holdings Plc, Oswaldo Cruz Foundation, Grifols SA, F. Hoffmann-La Roche Ltd, Siemens AG, Qiagen NV, bioMerieux SA, and DiaSorin SpA.
Hepatitis B tests market, by key companies
To know more about key companies, download a free report sample
Market Report Scope
Market size (Year – 2021) | $1.26 billion |
Key regions | North America, Europe, Asia Pacific, South America, and Middle East and Africa |
Key sub-segments | Hepatitis B Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) Tests, Hepatitis B Nucleic Acid Amplification Tests (NAATs), and Multi-parameter HIV, Hepatitis B, and Hepatitis C NAAT |
Key companies | Abbott Laboratories, Bio-Rad Laboratories Inc, Hologic Inc, Ortho Clinical Diagnostics Holdings Plc, Oswaldo Cruz Foundation, Grifols SA, F. Hoffmann-La Roche Ltd, Siemens AG, Qiagen NV, bioMerieux SA, and DiaSorin SpA |
This report provides:
- Insightful review of the key industry trends.
- Annualized total Hepatitis B tests devices market revenue by segment and market outlooks from 2015-2030.
- Market level data on units, average selling prices, and market values.
- Global, regional, and country-level market-specific insights including qualitative market-specific information with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country-specific insights on the market.
- SWOT analysis for Hepatitis B tests market.
- Competitive dynamics insights and trends provided for the Hepatitis B tests market.
- Country specific overview of the healthcare system.
- Country specific reimbursement policies.
- Country specific medtech regulatory landscape.
Reasons to Buy
- Understand the impact of COVID-19 on the Hepatitis B tests market.
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the Hepatitis B tests market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Hepatitis B tests market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Track device sales in the global and country-specific Hepatitis B tests market from 2015-2030.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Key Players
Frequently Asked Questions
The Hepatitis B tests market size was valued at $1.26 billion in 2021.
The key regions in the Hepatitis B tests market are North America, Europe, Asia Pacific, South America, and the Middle East and Africa.
The key segments in the Hepatitis B tests market are Hepatitis B Enzyme Immuno Assay/Enzyme-Linked Immunosorbent Assay (EIA/ELISA) Tests, Hepatitis B Nucleic Acid Amplification Tests (NAATs), and Multi-parameter HIV, Hepatitis B, and Hepatitis C NAAT.
Some of the key companies in the Hepatitis B tests market are Abbott Laboratories, Bio-Rad Laboratories Inc, Hologic Inc, Ortho Clinical Diagnostics Holdings Plc, Oswaldo Cruz Foundation, Grifols SA, F. Hoffmann-La Roche Ltd, Siemens AG, Qiagen NV, bioMerieux SA, and DiaSorin SpA.